Press releases

Month Year

Email alerts

Sep 28, 2016

Medtronic Receives FDA Clearance of TrailBlazer Angled Peripheral Support Catheter

TrailBlazer Angled Support Catheter Broadens Medtronic's Leading Peripheral Options Adding Full Spectrum of Angled Resources to Meet Provider Needs

DUBLIN - September 28, 2016 - Medtronic plc (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) has cleared the TrailBlazer(TM) angled support catheter for use in the...
Sep 28, 2016

Medtronic Receives FDA Approval for World's First Hybrid Closed Loop System for People with Type 1 Diabetes

The MiniMed® 670G System Features the Company's Most Advanced SmartGuard(TM) Algorithm To-Date

DUBLIN - Sept. 28, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval of its MiniMed® 670G...
Sep 27, 2016

Medtronic Announces First Live Experience of Sugar.IQ with Watson for People Living with Diabetes

Sugar.IQ with Watson Cognitive App to Preview at Health 2.0 Conference

DUBLIN and SANTA CLARA, Calif. - Sept. 27, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that Sugar.IQ with Watson, the first-of-its-kind cognitive app...
Sep 26, 2016

Medtronic's StealthStation® Cranial Software Receives FDA Clearance as an Aid for Deep Brain Stimulation Lead Placement

The Company Continues to Pioneer Innovations in Deep Brain Stimulation and Surgical Technologies by Launching the Only Fully-Integrated Procedural Solution for Neurosurgery

DUBLIN and SAN DIEGO - September 26, 2016 - Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) clearance of StealthStation® Cranial Software as an aid for deep...
Sep 20, 2016

Medtronic Valiant Captivia Demonstrates Safety and Efficacy at Three Years

New Clinical Data Presented in Complicated Type B Aortic Dissection at VIVA 2016

DUBLIN and LAS VEGAS - Sept. 20, 2016 - Medtronic plc (NYSE: MDT) today announced new data, demonstrating safety and efficacy at three years in acute complicated Type B aortic dissection patients...

Show per page